COMPARISON OF CLINICAL OBSERVATIONS BETWEEN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ALL-TRANS RETINOIC ACID AND CHEMOTHERAPY

Clinical observations were retrospectively compared between 2 matched groups of patients with acute promyelocytic leukemia (APL) each 20. The first group were treated with chemotherapy, the other with all-tram retinoic acid (ATRA) alone at a dose of 45-60mg/M~2/d. The complete remission (CR) rate of ATRA group was significantly higher than that of chemotherapy (90% vs 55%). The time for obtaining CR as well as the duration of fever and hospitalization were shorter and the amount of blood transfused was less in the former than in the latter group. Seven cases were complicated by DIC and 4 died in the group of chemotherapy, while no case was by of DIC or death in the ATRA group. The mechanism was discussed. ATRA is an alternative effective drug for remission induction therapy in APL with high rate of CR.     

吉西他滨为主的联合方案治疗晚期乳腺癌临床观察

目的 观察吉西他滨联合阿霉素或顺铂治疗晚期乳腺癌的疗效和不良反应.方法 晚期经病理确诊的乳腺癌患者45例,32例既往使用蒽环类治疗失败,予以吉西他滨联合顺铂(GP方案)化疗,13例未曾应用蒽环类治疗,予以吉西他滨联合阿霉素(GA方案)化疗,吉西他滨剂量1000 mg/m2,第1、8天,其他药物使用常规剂量,21 d为1个周期,2个周期后评价疗效,有效者为化疗4个周期以上.结果 45例患者中完全缓解(CR) 5例,部分缓解(PR)15例,稳定(SD)20例,进展(PD)5例,总有效率(CR+PR)为53.3%,不良反应主要为恶心、呕吐、脱发、骨髓抑制,但均可耐受.无化疗相关死亡病例.结论 吉西他滨为主的联合化疗方案治疗晚期乳腺癌疗效较好,不良反应可以耐受. Abstract： Objective To evaluate the efficacy and toxicity of gemcitabine based combination chemotherapy in patients with advanced breast cancer.Methods Forty-five patients with a pathologic diagnosis were enrolled in the study,patients previously failured to dariamycin-based chemotherapy received the regimen of gemcitabine plus cisplation(GP regimen),the others received gemcitabine plus doxorubicin(GA regimen), the patients were treated with gemcitabine 1000 mg/m2 infusion for 10 minutes on day 1,8. Other agents were treated with regular doses,the regimen was repeated every 21 days and the clinical response was assessed after two cycles.The effective patients recieved at least four cycles.Results CR 5 cases, PR 15 cases,SD 20 cases,PD 5 cases,the overall response rate was 44.4 %(20/45),the toxicities included myelosuppression,nausea,vomiting and alopecia,but they were tolerable, there was no death during treatment.Conclusions The regimen based on is effective in the treatment of patients with advanced breast cancer,and the toxicities are tolerable.     

急性早幼粒细胞白血病治疗新对策

目的急性早幼粒细胞白血病(APL)治疗新对策.方法AS2O3联合ATRA治疗初治和复发APL患者20例(可评价的患者18例).治疗方法如下:(AS2O3)0.16mg.k.-1.a-1加50g/L葡萄糖溶液500ml静脉点滴,持续4-6h,1次/d;ATRA25mg.m-2.a-1,分2-3次服用.结果17例患者获得完全缓解(CR),CR率94.4%,14例初治患者均获得CR,4例复发患者中3例取得CR,均在30d内达CR.没有发现明显的不良反应.结论ATRA联合AS2O3治疗APL患者不仅能获得好的疗效,而且能缩短达CR的时间.     

LEUKOCYTOSIS AND RETINOIC ACID SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENIC TRIOXIDE

ALL-trans-retinoic acid ATRA),as the first-line drug,induces complete remission CR)in80%to90%of patients with acute promyelo-cytic leukemia APL)and significantly improves the out-come of the patients with APL.1Although ATRA is gener-ally well tolerated,40…     

急性早幼粒细胞白血病合并弥漫性血管内凝血183例疗效分析

目的:探讨急性早幼粒细胞白血病(APL)合并弥漫性血管内凝血(DIC)的治疗效果。方法:对不同治疗方案的疗效进行比较。结果:采用ATRA+As2O3或者两者交替组获得CR中位时间分别为34d、35.5d,单用ATRA获得CR中位时间为62d,P<0.05,差异有显著性。ATRA+As2O3组或两者交替组,3a无病生存率分别为78%和80%,与单用ATRA组比较,差异有显著性(P<0.05),DIC纠正时间为16d~18d,三种治疗方案无明显差异。15例行HSCT者,仅2例复发,其余13例中位无病生存时间(DFS)为13.5a,该13例PCR检测PML-RARα融合基因阴性。结论:应用ATRA+As2O3或两者交替加成分血、抗纤溶纠正DIC及其化疗治疗APL获得CR时间明显缩短,而且3a无病生存率相对较高。缓解后6个月进行HSCT者,DFS可进一步延长。     

Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study

Objective: To evaluate the association between Chinese medicine(CM) therapy and disease-free survival(DFS) outcomes in postoperative patients with non-small cell lung cancer(NSCLC). Methods: This multiple-center prospective cohort study was conducted in 13 medical centers in China. Patients with stage Ⅰ,Ⅱ, or ⅢA NSCLC who had undergone radical resection and received conventional postoperative treatment according to the National Comprehensive Cancer Network(NCCN) guidelines were recruited. The recruited patients were divided into a CM treatment group and a control group according to their wishes. Patients in the CM treatment group received continuous CM therapy for more than 6 months or until disease progression. Patients in the control group received CM therapy for less than 1 month. Fol ow-up was conducted over 3 years. The primary outcome was DFS, with recurrence/metastasis rates as a secondary outcome. Results: Between May 2013 and August 2016, 503 patients were enrol ed into the cohort; 266 were classified in the CM treatment group and 237 in the control group. Adjusting for covariates, high exposure to CM was associated with better DFS [hazard ratio(HR) = 0.417, 95% confidential interval(CI): 0.307–0.567)]. A longer duration of CM therapy(6–12 months, 12–18 months, 24 months) was associated with lower recurrence and metastasis rates(HR = 0.225, 0.119 and 0.083, respectively). In a subgroup exploratory analysis, CM therapy was also a protective factor of cancer recurrence and metastasis in both stage Ⅱ–ⅢA(HR=0.50, 95% CI: 0.37–0.67) and stage ⅢA NSCLC postoperative patients(HR = 0.48, 95% CI: 0.33–0.71), DFS was even longer among CM treatment group patients.Conclusions: Longer duration of CM therapy could be considered a protective factor of cancer recurrence and metastasis. CM treatment is associated with improving survival outcomes of postoperative NSCLC patients in China.(Registration No. ChiC TR-OOC-14005398)     

Treatment of acute promyelocytic leukemia with all-trans retinoic acid. A five-year experience.

From January 1986 to April 1991, 107 consecutive patients with acute promyelocytic leukemia (APL) were treated with retinoic acid (RA) at an oral dose of 45-60mg/m2/d, alone or in combination with chemotherapy. In 91 cases treated with RA alone, 74 (81.3%) achieved complete remission (CR). The CR rate was 75% in 16 cases treated with combined therapy. Among 50 patients closely followed for a median of 36 months (4-60), 10 received RA as continuation therapy (Group A), 10 received chemotherapy (Group B) and 30 were treated with RA and chemotherapy alternately in regular sequence (Group C). The mean survival time was 8.4, 9.7 and 21.6 months, respectively, for the 29 cases who died. The survival probability was higher in Group C than in Group A and B (P < 0.01). RA did not provoke or aggravate DIC, it did not cause marrow hypoplasia or aplasia. The side effects were relatively mild as compared with chemotherapy. CFU-GM markedly reduced before treatment was restored to normal level after CR, while the result for L-CFU was reversed. In 40 cases examined for in vitro induction of differentiation, 39 responders were culminating in CR. Aberrant karyotype t (15; 17) was positive in all 47 cases examined prior to the treatment. It disappeared in all of the 20 cases studied after achieving CR, and reappeared in 3 cases following relapse. The best regimen to maintain a longer CR duration and survival time in this study was to use RA and chemotherapy alternately as continuation therapy.

     

维甲酸、三氧化二砷双诱导及联合化疗序贯治疗初治急性早幼粒细胞白血病

目的 观察以全反式维甲酸(ATRA)和三氧化二砷(ATO)双诱导,而后联合化疗序贯治疗初治急性早幼粒细胞白血病(APL)的疗效和不良反应.方法 对初治的35例APL患者以ATRA、ATO进行双诱导,完全缓解(CR)后,采用蒽环类为主的化疗方案、ATRA+ATO、6+MP+ATRA+MTX三种方案循环序贯缓解后治疗,总治疗时间2年.结果 35例初治APL患者中,1例入院48小时内因脑出血死亡,未纳入评价,其余34例全部获得CR,CR率100％,达到CR中位时间为26( 14～49)天.平均随访时间为62个月(12 ～ 82个月),1例诱导缓解后未再次入院治疗,1例失访,余32例均无血液学及基因学复发,预计7年OS和DFS均为100％.3例(8.8％)发生维甲酸综合征(RAS),余无严重不良反应发生.结论 ATRA联合ATO双诱导治疗初治APL患者CR率高、达CR时间短,蒽环类为主的化疗方案、ATRA+ATO、6+MP+ATRA+MTX序贯进行诱导缓解后治疗疗效好,不良反应轻,耐受性好.     

三氧化二砷与化疗分别联合全反式维甲酸治疗急性早幼粒细胞白血病的临床疗效研究

目的：观察三氧化二砷（ATO）联合全反式维甲酸（ATRA）与以阿糖胞苷（Ara‐C）为主联合ATRA的化疗方案诱导缓解治疗急性早幼粒细胞白血病（APL）的疗效。方法将2002年1月至2008年8月该科收治65例初治 APL 患者分为治疗组和对照组,治疗组（ATRA 联合 ATO 治疗,27例）和对照组[ATRA 联合 DA（柔红霉素＋ Ara‐C）、HA（高三尖酯碱＋ Ara‐C）、NA （米托蒽醌＋ Ara‐C）等以 Ara‐C 为主联合化疗组,38例]。观察两组患者在完全缓解率（CR）、到达完全缓解时间、总生存率（OS）、无事件发生率（EFS）、5年无病生存率（DFS）及不良反应的差异。结果治疗组 CR 为81．48％,获得完全缓解平均时间（28．50±3．97）d ;对照组完全缓解为68．42％,获得完全缓解平均时间为（30．56±2．39）d ,两组比较差异无统计学意义（P＞0．05）。两组完全缓解患者继续序贯治疗5年 OS 分别为51．9％和50．0％,差异无统计学意义（P＞0．05）。两组完全缓解患者的5年 EFS 分别为48．1％和39．5％,二者差异无统计学意义（P＞0．05）。两组患者5年 DFS 分别是55．6％和67．6％,差异无统计学意义（P＞0．05）。治疗组不良反应中骨髓抑制明显低于对照组（P＜0．05）。结论 ATRA 联合 ATO 治疗初治 APL 患者可以获得较高的完全缓解、OS 、EFS 及5年 DFS ,ATRA 联合化疗方案与之疗效相似。但 ATRA ＋ ATO 骨髓抑制较 ATRA 联合治疗低,可能降低早期死亡风险。     

Long-term survey of outcome in acute promyelocytic leukemia

Ａｃｕｔｅｐｒｏｍｙｅｌｏｃｙｔｉｃｌｅｕｋｅｍｉａ (ＡＰＬ)ｉｓａｄｉｓｔｉｎｃｔｓｕｂｔｙｐｅｏｆａｃｕｔｅｌｅｕｋｅｍｉａｃｈａｒａｃｔｅｒｉｚｅｄｂｙａｂａｌａｎｃｅｄｒｅｃｉｐｒｏｃａｌｔｒａｎｓｌｏｃａｔｉｏｎｂｅｔｗｅｅｎｃｈｒｏｍｏｓｏｍｅ 15ａｎｄ 17ｒｅｓｕｌｔｉｎｇｉｎｔｈｅｃｈｉｍｅｒｉｃｇｅｎｅｅｎｃｏｄｉｎｇＰＭＬ ＲＡＲαｐｒｏｔｅｉｎ 1Ａｌｌ ｔｒａｎｓｒｅｔｉｎｏｉｃａｃｉｄ (ＡＴＲＡ)ｉｎｄｕｃｅｄｉｆｆｅｒｅｎｔｉａｔｉｏｎｏｆｐｒｏｍｙｅｌｏｃｙｔｅｓｉｎｔｏｍ…     

双诱导联合蒽环类抗生素治疗初治急性早幼粒细胞白血病疗效观察

目的观察以全反式维甲酸（all-trans retinoic acid,ATRA）和亚砷酸（As2O3）双诱导,联合蒽环类抗生素（anthracycline,ATC）为主的治疗方案治疗急性早幼粒细胞白血病（APL）的疗效。方法对初治APL患者以ATRA和Asz03进行双诱导,联合DA方案化疗,达完全缓解（CR）后,以ATC为主的方案巩固化疗6疗程,以后以化疗、ATRA、As2O3交替序贯维持治疗,化疗方案中仍以ATC为主。总治疗时间3年。14例患者接受了PML／RARα融合基因监测。结果21例初治APL患者中,除2例早期死亡外,其余19例诱导治疗后均达CR,经巩固、维持治疗,此19例患者至今均为持续完全缓解（CCR）状态,其中CCR5年以上2例,3年以上6例。无患者出现严重或不可逆的毒副反应。接受PML／RARα融合基因检测的14例患者,初诊时均为阳性,巩固治疗结束时均转为阴性,在以后监测中无一例转阳。结论双诱导联合ATC治疗初治APL,疗效可靠,毒副反应小。     

急性早幼粒细胞白血病疗效随访(附78例报告)

目的评估应用不同治疗方案治疗急性早幼粒细胞白血病(APL)的近、远期疗效。方法回顾性分析78例APL患者的诱导缓解及缓解后治疗,并作5年随访分析。结果75例(96．2％)患者获得完全缓解(CR),全反式维甲酸(ATRA)治疗组(49例)和ATRA 化疗治疗组(24例)的CR率分别为95．9％和95．8％,两组间的差异无统计学意义(P>0．05)。75例达CR的患者进入缓解后治疗,应用ATRA 化疗(18例)、单用化疗序贯(48例)及大剂量阿糖胞苷(HDAE),7例)的复发率分别为66．7％、35．4％和85．7％,3组间的差异有统计学意义(P值均<0．05)。75例CR患者的1、3、5年总生存率分别为81．5％、61．8％和49．1％,无病生存期分别为78．2％、59．0％和49．1％。中位生存期为86．7个月(95％CI为66．7～106．8个月)。结论APL,诱导缓解率高,远期随访中缓解后应用化疗序贯的复发率较低。     

初治急性早幼粒细胞白血病缓解后三氧化二砷和常规化疗巩固治疗疗效分析

 【目的】 探讨初治急性早幼粒细胞白血病(APL)缓解后三氧化二砷(ATO)和常规化疗交替巩固治疗的长期疗效和安全性。【方法】 自2003年5月至2009年12月,初治APL患者完全缓解(CR)后采用ATO和常规化疗交替巩固治疗方案:ATO 10 mg/d每周5 d × 4周或连续20 d为1疗程,化疗为常规剂量蒽环类药物-阿糖胞苷“3+7”方案。【结果】 54例初治APL患者CR后采用ATO和常规化疗交替巩固治疗方案,男29例,女25例,中位年龄31岁,ATO和化疗巩固中位疗程数各4(2 ~ 8)个,ATO总剂量中位数15.1(5.9 ~ 34.8)mg/kg。ATO巩固治疗结束阶段常出现3/4级中性粒细胞减少,但不增加细菌感染率,其它毒副作用轻微、可逆。巩固治疗期间无治疗相关死亡,所有患者在巩固治疗期间获分子生物学完全缓解。中位随访39(12 ~ 91)个月,复发2例,其CR期分别为25和46个月;3年、5年无白血病生存率(LFS)和累积复发风险分别为(97.7 ± 2.3) %、(93.4 ± 4.7) % 和(2.4 ± 2.3)%、(6.8 ± 4.7) %,其中CR > 5年17例(占31%)、> 3年29例(占54%),无ATO慢性蓄积中毒和继发第二恶性肿瘤的发生。COX回归模型单因素分析表明患者年龄、性别、病初WBC、Hb、PLT、LDH值、外周血和骨髓异常早幼粒细胞比例以及诱导治疗方案中维甲酸是否联合ATO与LFS均无显著相关(P > 0.05)。【结论】 初治APL缓解后采用ATO联合常规化疗安全有效,可获得更高的长期无病生存率。     

全反式维甲酸、三氧化二砷联合化疗治疗初治急性早幼粒细胞白血病的临床观察

目的观察以全反式维甲酸(ATRA)和三氧化二砷(ATO)双诱导,联合化疗治疗初治急性早幼粒细胞白血病(APL)的疗效。方法对初治APL患者35例以ATRA和ATO进行双诱导,联合DA(柔红霉素+阿糖胞苷)方案化疗,达完全缓解(CR)后,采用DA、MA(米托蒽醌+阿糖胞苷)、HA(高三尖杉酯碱+阿糖胞苷)、MDAra-c(中剂量阿糖胞苷)、ATO序贯治疗,于每疗程化疗结束后连服ATRA 15 d,总治疗时间3年。结果35例初治APL患者中,1例早期死亡,未纳入评价,其余34例中,33例(97.1%)获得CR,1例(2.9%)未缓解(死于重症肺部感染)。2例(5.9%)发生维甲酸综合征(RAS)。随访至2009年5月,复发2例。3年总生存率、无病生存率分别为94.12%、91.18%。结论双诱导联合化疗治疗初治APL疗效可靠,患者可耐受治疗。     

改良儿童方案治疗年轻成人费城染色体阴性急性淋巴细胞白血病疗效评价

目的:评估改良儿童方案治疗年轻成人费城染色体(Ph)阴性急性淋巴细胞白血病的疗效。方法:纳入2013年1月至2014年9月年轻成人Ph阴性急性淋巴细胞白血病35例,患者均采用改良儿童方案化疗,随访并评估患者疗效。结果:32例(91%)达到完全缓解(complete remission,CR),其中24例维持CR,7例复发,4例死于疾病复发,1例死于感染;24个月无病生存率(disease-free survival,DFS)为68.6%,24个月总生存率(overall survival,OS)为77.1%。结论:适当减低化疗强度的儿童方案治疗年轻成人Ph阴性急性淋巴细胞白血病有较好的疗效和安全性。     

大剂量柔红霉素联合标准剂量阿糖胞苷对中青年初发急性髓系白血病患者的近、远期疗效

目的分析大剂量柔红霉素（DNR）联合标准剂量阿糖胞苷（Ara-C）对中青年初发急性髓系白血病（AML）患者的近、远期效果。方法选取2011年1月-2015年5月该院血液内科收治的并接受的大剂量[60mg/（m2·d）]DNR 联合100 mg/（m2·d）Ara-C 的DA 方案行诱导化疗的133 例中青年初治AML 患者为研究对象,归为观察组。并随机选择同期该院接受标准剂量DA 诱导方案[45 mg/（m2·d）DNR 联合100 mg/（m2·d）Ara-C]的125例中青年初治AML 患者为对照组。比较两组的完全缓解率（CR）、各不良反应的发生率、早期死亡率、血中性粒细胞绝对计数（ANC）减少的持续时间以及血小板（PLT）减少持续时间,并均进行随访,截止至2016 年12月,比较两组的1、2 及3 年的总生存率（OS）和无瘤生存率（DFS）,采用单因素与多因素Cox 比例风险模型筛选出影响达到CR的观察组患者OS 和DFS 的影响因素。结果①两组的化疗前基线资料比较,差异无统计学意义（p >0.05）,具有可比性。②观察组、对照组患者行1 个疗程诱导化疗后的CR 率分别为67.7%和57.6%,两组比较差异无统计学意义（p >0.05）。观察组患者2 个疗程诱导化疗后的总CR 率为82.0%,高于对照组的70.4%,差异有统计学意义（p <0.05）。两组的各不良反应发生率、早期死亡率、ANC 和PLT 减少的持续时间比较,差异无统计学意义（p >0.05）。③经过诱导化疗达到CR后,两组分别有103 例（95.%）和84 例（67.2%）患者均行1～4 个疗程的巩固化疗,之后分别有21 例（15.8%）、17 例患者（13.6%）行异基因造血干细胞移植,2 例（1.5%）、1 例（0.8%）行自体造血干细胞移植。截止至末次随访时,两组患者的中位随访时间分别为26.8 和28.0个月,两组化疗后1、2 及3 年的OS 和DFS 比较,差异无统计学意义（p >0.05）。④多因素Cox 回归分析结果表明,对观察组患者诱导化疗达到CR 的109 例患者而言,预后危险分层、接受≥2 个疗程大剂量Ara-C 巩固化疗是影响患者OS 的影响因素（p <0.05）;预后危险分层、FMS 样的酪氨酸激酶3 -内部串联重复（FLT3-ITD）突变阳性是影响患者DFS 的影响因素（p <0.05）。结论与标准剂量DNR 相比,大剂量DNR 联合标准剂量Ara-C 能提高中青年初发AML 患者的CR 率,且不增加不良反应的发生风险,但对改善其远期生存状况未见明显优势。     

79例儿童t(8;21)急性髓系白血病的核型及预后分析

目的 调查儿童t(8;21)急性體系白血病(AML)的核型异常情况,评估缓解后治疗强度对预后的影响.方法 采用形态学、免疫学和细胞遗传学(MIC)方法对79例儿童t(8;21)AML患者进行检测确诊.诱导缓解治疗采用高三尖杉酯碱联合阿糖胞苷(HA)/柔红霉素联合阿糖胞苷(DA)/高三尖杉酯碱、阿糖胞苷和柔红霉素联合(HAD)方案.缓解后进行异基因造血干细胞移植或5～7疗程的联合化疗.结果 79例患儿中,55例(69.6%)有附加染色体异常,其中40例(50.6%)伴性染色体丢失,9例(11.4%)为del(9q),7例(8.9%)为复杂变异型t(8;21)异常.3例患儿染色体数量在90条以上且伴双重t(8;21)四倍体核型,预后均不良.1、2疗程完全缓解(CR)率分别力81.7%(49/60)和94.8%(55/58);3年无事故生存率、无病生存(DIS)率和总生存率分别为(26.2 ± 6.8)%、(31.3 ± 6.7)%和(27.6 ± 6.6)%;29例患儿缓解后治疗疗程数为5个或以上,其3年DFS率为(51.7 ± 9.3)%.单纯t(8;21)±性染色体丢失组与伴其他附加染色体异常组患儿的3年DFS率差异无统计学意义(P=0.36).大剂量阿糖胞苷组患儿的3年DFS率明显优于标准化疗组(66.7% vs.27.3%,P=0.03).结论 多数儿童t(8;21)AML患者伴有附加染色体核型异常,附加染色体核型异常对患儿生存没有不良影响.染色体数量在90条以上且伴双重t(8;21)四倍体核型少见,但预后不良.儿童伴t(8;21)AML治疗CR率高,远期疗效好.采用大剂量阿糖胞苷作为缓解后治疗能提高远期疗效.     

Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine <Emphasis Type="Italic">versus</Emphasis> High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics

In this study, we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine (HAM) with that of high-dose cytarabine alone (HiDAC) as consolidation regimens in non-acute promyelocytic leukemia (APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics. A total of 62 patients from Shenzhen People's Hospital were enrolled in this study. All patients enrolled received standard induction chemotherapy and achieved the first complete remission (CR1). In these patients, 24 received HiDAC and 38 received HAM as consolidation. The median relapse free survival (RFS) and overall survival (OS) were similar between these two consolidation regimens. Even in subgroup analysis according to risk stratification, the combination regimen conferred no benefit in longterm outcome in patients with favorable or intermediate cytogenetics. However, in patients receiving HAM regimen, the lowest neutrophil count was lower, neutropenic period longer, neutropenic fever rate higher, and more platelet transfusion support was required. HAM group also tended to have higher rate of sepsis than HiDAC group. According to our results, we suggest that combination treatment with mitoxantrone and intermediate-dose cytarabine has limited value as compared to HiDAC, even in young non-APL AML patients with favorable and intermediate cytogenetics.     

全反式维甲酸和三氧化二砷联合诱导分化治疗急性早幼粒细胞白血病

目的 对比研究急性早幼粒细胞白血病(APL)首次诱导治疗使用全反式维甲酸(ATRA)和三氧化二砷(AS2O3)联合方案与单用ATRA诱导方案的缓解率、缓解时间及生存率(OS),探讨两种方案的安全性和有效性.方法 初治APL患者53例,按照不同的诱导缓解治疗方案随机分为双诱导组(研究组)、单诱导组(对照组),比较两组的完...